In vitro activity of moxifloxacin (8-methoxyquinolone) alone or in combination with cefotaxime against group B streptococci;Activité in vitro de la moxifloxacine (8-méthoxyquinolone) seule ou en association avec le céfotaxime sur les streptocoques du groupe B

Pathologie Biologie

Volumn 55, Issue 8-9, 2007, Pages 412-417

  Jacquier, H ^a   Cruaud, P ^a   Poilane, I ^a   Lachassinne, E ^a   Gaudelus, J ^a   Collignon, A ^a  

^a HÔPITAL JEAN VERDIER   (France)

Author keywords

Cefotaxime; Moxifloxacin; Neonatal; Streptococcus agalactiae

Indexed keywords

CEFOTAXIME; MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL GROWTH; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATION; DRUG CEREBROSPINAL FLUID LEVEL; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NEWBORN INFECTION; NONHUMAN; STREPTOCOCCUS AGALACTIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTEREMIA; CEFOTAXIME; DRUG THERAPY, COMBINATION; HUMANS; INFANT, NEWBORN; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; QUINOLINES; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 35448971918     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2007.07.004     Document Type: Article

References (14)

1. Lejeune C., Floch-Tudal C., Montamat S., and Jaby-Sergent M. Conduite à tenir face à une colonisation materno-infantile à streptocoques du groupe B. Med. Ther. Pediatr. 2 1 (1999) 47-54
2. Prévention anténatale du risque infectieux bactérien néonatal précoce. Haute Autorité de santé 2002 (http://www.has-sante.fr/portail/).
3. Schrag S.J., Zywicki S., Farley M.M., Reingold A.L., Harrison L.H., Lefkowitz L.B., et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med. 342 1 (2000) 15-20
4. Bingen E., Levy C., de la Rocque F., Boucherat M., Varon E., Alonso J.M., et al. Bacterial meningitis in children: a French prospective study. Clin. Infect. Dis. 41 7 (2005) 1059-1063
5. Diagnostic et traitement curatif de l'infection bactérienne précoce du nouveau-né. Haute Autorité de santé 2002 (http://www.has-sante.fr/portail/).
6. Gendrel D., and Aujard Y. Les quinolones en pédiatrie. Arch. Pediatr. 2 5 (1995) 409-411
7. Schaad U.B., Abdus Salam M., Aujard Y., Dagan R., Green S.D., Peltola H., et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr. Infect. Dis. J. 14 1 (1995) 1-9
8. Ostergaard C., Sorensen T.K., Knudsen J.D., and Frimodt-Moller N. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob. Agents Chemother. 42 7 (1998) 1706-1712
9. e édition (2006), ESKA Ed, Paris
10. Weisner A.M., Johnson A.P., Lamagni T.L., Arnold E., Warner M., Heath P.T., et al. Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin. Infect. Dis. 38 9 (2004) 1203-1208
11. Kim K.S., and Anthony B.F. Penicillin tolerance in group B streptococci isolated from infected neonates. J. Infect. Dis. 144 5 (1981) 411-419
12. Betriu C., Gomez M., Sanchez A., Cruceyra A., Romero J., and Picazo J.J. Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci. Antimicrob. Agents Chemother. 38 9 (1994) 2183-2186
13. Goldwater P.N. Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. Int. J. Antimicrob. Agents 26 5 (2005) 408-411
14. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr. Infect. Dis. J. 22 12 (2003) 1128-1132